CSIMarket
 


Atara Biotherapeutics Inc   (ATRA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

ATRA's Capital Expenditures Growth by Quarter and Year

Atara Biotherapeutics Inc 's Capital Expenditures results by quarter and year




ATRA Capital Expenditures (in millions $) FY 2020 FY 2019 FY 2018 FY 2017
IV Quarter December - 4.20 4.17 9.70
III Quarter September 0.50 1.49 4.50 6.19
II Quarter June 2.08 0.74 7.45 3.14
I Quarter March 1.33 0.80 19.81 1.21
FY   3.91 7.23 35.93 20.24



ATRA Capital Expenditures third quarter 2020 Y/Y Growth Comment
Atara Biotherapeutics Inc reported drop in Capital Expenditures in the third quarter by -66.24% to $ 0.50 millions, from the same quarter in 2019.
The fall in the third quarter Atara Biotherapeutics Inc 's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures drop of -55.22%.

Looking into third quarter results within Biotechnology & Drugs industry 49 other companies have achieved higher Capital Expenditures growth. While Atara Biotherapeutics Inc ' s Capital Expenditures meltdown of -66.24% ranks overall at the positon no. 1242 in the third quarter.




ATRA Capital Expenditures ( Y/Y Growth %) 2020
2019 2018 2017
IV Quarter December - 0.72 % -57.01 % 602.9 %
III Quarter September -66.24 % -66.89 % -27.3 % 725.33 %
II Quarter June 181.08 % -90.07 % 137.26 % 252.81 %
I Quarter March 66.25 % -95.96 % 1537.19 % 348.15 %
FY   - -79.88 % 77.52 % 515.2 %

Financial Statements
Atara Biotherapeutics Inc 's third quarter 2020 Capital Expenditures $ 0.50 millions ATRA's Income Statement
Atara Biotherapeutics Inc 's third quarter 2019 Capital Expenditures $ 1.49 millions Quarterly ATRA's Income Statement
New: More ATRA's historic Capital Expenditures Growth >>


ATRA Capital Expenditures (Quarter on Quarter Growth %)

2020
2019 2018 2017
IV Quarter December - 181.88 % -7.33 % 56.7 %
III Quarter September -75.82 % 101.35 % -39.6 % 97.13 %
II Quarter June 56.39 % -7.5 % -62.39 % 159.5 %
I Quarter March -68.33 % -80.82 % 104.23 % -12.32 %
FY (Year on Year)   - -79.88 % 77.52 % 515.2 %




Capital Expenditures third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #50
Healthcare Sector #225
Overall #1242

Capital Expenditures Y/Y Growth Statistics
High Average Low
-7.87 % -55.22 % -82.66 %
(Sep 30 2020)   (Sep 30 2019)
Capital Expenditures third quarter 2020 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #50
Healthcare Sector #225
Overall #1242
Capital Expenditures Y/Y Growth Statistics
High Average Low
-7.87 % -55.22 % -82.66 %
(Sep 30 2020)   (Sep 30 2019)

Capital Expenditures by Quarter for the Fiscal Years 2017, 2018, 2019, 2020

Atara Biotherapeutics Inc 's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1835.71 % 112.61 % -100 %
(Dec 31 2015)  


ATRA's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2020 Atara Biotherapeutics Inc realized fall in Capital Expenditures sequentially by -75.82% to $ 0.50 millions, from $ 2.08 millions released in the previous reporting period.

Although cyclical factors normally elevate III. Quarter 2020 Capital Expenditures, it simply has not been enough to recover ATRA's performance, Andrew  Roberts, Biotechnology & Drugs industry consultant pointed out.

Within Biotechnology & Drugs industry 116 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Atara Biotherapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2648.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #117
Healthcare Sector #485
Overall #2648
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #117
Healthcare Sector #485
Overall #2648
Capital Expenditures Q/Q Growth Statistics
High Average Low
1835.71 % 112.61 % -100 %
(Dec 31 2015)  


ATRA's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2020 Atara Biotherapeutics Inc realized fall in Capital Expenditures from the second quarter by -75.82% to $ 0.50 millions, from $ 2.08 millions declared in the previous qaurter.

Some periodic influence have not rescue the III. Quarter for the Atara Biotherapeutics Inc , Andrew  Roberts, Biotechnology & Drugs industry consultant wrote, he voiced certan caution towards Atara Biotherapeutics Inc 's direction, he sees further headwinds ahead for Atara Biotherapeutics Inc and mentioned that average sequential Capital Expenditures growth is at 112.61% for Atara Biotherapeutics Inc .

Within Biotechnology & Drugs industry 116 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Atara Biotherapeutics Inc 's Capital Expenditures growth quarter on quarter, overall rank is 2648.


Atara Biotherapeutics Inc 's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
12 Months Ending
(Dec 31 2019)
12 Months Ending
(Sep 30 2019)
Cumulative Capital Expenditures 12 Months Ending $ 6.62 $ 7.61 $ 6.27 $ 9.90 $ 7.19
Y / Y Capital Expenditures Growth (TTM) -7.87 % -25.43 % -62.93 % -76.11 % -82.66 %
Year on Year Capital Expenditures Growth Overall Ranking # 1242 # 1795 # 1412 # 0 # 0
Seqeuential Capital Expenditures Change (TTM) -12.93 % 21.34 % 9.37 % -2.94 % -29.52 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1886 # 314 # 186 # 0 # 0




Cumulative Capital Expenditures growth Comment
Atara Biotherapeutics Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jun 30 2020. If the fiscal year would end in Sep 30 2020, Atara Biotherapeutics Inc 's annual Capital Expenditures drop would be -7.87% year on year to $7 millions.

In the Healthcare sector 224 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1242, from total ranking in previous quarter at 1795.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
21.34 %
-9.06 %
-39.68 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 79
Healthcare Sector # 225
Overall # 1242

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
-7.87 %
-55.22 %
-82.66 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 79
Sector # 343
S&P 500 # 1886
Cumulative Capital Expenditures growth Comment
Atara Biotherapeutics Inc showed decline, but improvement compare to trailing twelve month Capital Expenditures decrease in Jun 30 2020. If the fiscal year would end in Sep 30 2020, Atara Biotherapeutics Inc 's annual Capital Expenditures drop would be -7.87% year on year to $7 millions.

In the Healthcare sector 224 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 1242, from total ranking in previous quarter at 1795.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
21.34 %
-9.06 %
-39.68 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry # 79
Healthcare Sector # 225
Overall # 1242

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
-7.87 %
-55.22 %
-82.66 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 79
Sector # 343
S&P 500 # 1886




Other Capital Expenditures Growth
Biotechnology & Drugs Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
ATRA's Capital Expenditures Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for ATRA's Competitors
Capital Expenditures Growth for Atara Biotherapeutics Inc 's Suppliers
Capital Expenditures Growth for ATRA's Customers

You may also want to know
ATRA's Annual Growth Rates ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Sep 30 2020 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2020
Merit Medical Systems Inc -0.09 %$ -0.091 millions
Select Medical Holdings Corp -1.02 %$ -1.015 millions
Johnson and Johnson -1.07 %$ -1.074 millions
Acceleron Pharma inc -1.12 %$ -1.120 millions
Bausch Health Companies Inc -1.20 %$ -1.205 millions
Illumina Inc -2.04 %$ -2.041 millions
Baudax Bio Inc -2.23 %$ -2.229 millions
Addus Homecare Corporation -2.78 %$ -2.775 millions
Sangamo Therapeutics Inc -3.02 %$ -3.024 millions
Icu Medical Inc -3.10 %$ -3.100 millions
Uniqure N v -3.24 %$ -3.236 millions
Phibro Animal Health Corp -3.32 %$ -3.322 millions
Eidos Therapeutics Inc -4.46 %$ -4.464 millions
Dexcom Inc -4.63 %$ -4.628 millions
Quest Diagnostics Inc -5.21 %$ -5.208 millions
Seaspine Holdings Corporation -6.05 %$ -6.051 millions
Biogen Inc -6.66 %$ -6.659 millions
Beigene Ltd -7.10 %$ -7.100 millions
Nephros Inc -7.14 %$ -7.143 millions
National Healthcare Corp -8.47 %$ -8.467 millions
Zoetis Inc -8.59 %$ -8.594 millions
Integrated Biopharma Inc -8.62 %$ -8.621 millions
Davita Inc -8.68 %$ -8.678 millions
Nuvasive Inc -8.77 %$ -8.772 millions
Chemed Corporation -8.93 %$ -8.933 millions
Steris Plc -9.28 %$ -9.280 millions
Dentsply Sirona Inc -9.40 %$ -9.402 millions
Tabula Rasa Healthcare inc -9.71 %$ -9.706 millions
Mylan N v -9.91 %$ -9.906 millions
Sientra inc -11.30 %$ -11.299 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

HTH's Profile

Stock Price

HTH's Financials

Business Description

Fundamentals

Charts & Quotes

HTH's News

Suppliers

HTH's Competitors

Customers & Markets

Economic Indicators

HTH's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071